Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This single-arm, Phase II study was designed to evaluate the safety and efficacy of
Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) combination with Apatinib in
participants with ES-SCLC who was response or stable disease after firstline standard
chemotherapy. Participants will be receive camrelizumab +apatinib on 21-day cycles until
progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria
in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent
radiographic PD or symptomatic deterioration.